Federated Hermes
MRSN

Federated Hermes’s Mersana Therapeutics MRSN Stock Holding History

Federated Hermes’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,349
Closed -$263K – 2146
2024
Q4 		$263K Sell
7,349
-1
-0% -$52 ﹤0.01% 1444
2024
Q3 		$347K Sell
7,350
-70
-0.9% -$3.09K ﹤0.01% 1400
2024
Q2 		$373K Buy
7,420
+7,413
+105,900% +$536K ﹤0.01% 1376
2024
Q1 		$788 Buy
+7
New +$696 ﹤0.01% 1967
2023
Q4 		– Sell
-56
Closed -$1.77K – 2140
2023
Q3 		$1.77K Sell
56
-5,570
-99% -$265K ﹤0.01% 1980
2023
Q2 		$463K Buy
+5,626
New +$823K ﹤0.01% 1398
2022
Q2 		– Sell
-28,957
Closed -$2.89M – 2235
2022
Q1 		$2.89M Buy
28,957
+20,854
+257% +$2.44M 0.01% 927
2021
Q4 		$1.26M Buy
+8,103
New +$1.58M ﹤0.01% 1195
2021
Q1 		– Sell
-7
Closed -$5K – 2310
2020
Q4 		$5K Sell
7
-11,134
-100% -$6.19M ﹤0.01% 2056
2020
Q3 		$5.19M Buy
11,141
+6,589
+145% +$3.33M 0.01% 721
2020
Q2 		$2.66M Buy
4,552
+2,024
+80% +$691K 0.01% 888
2020
Q1 		$369K Buy
+2,528
New +$442K ﹤0.01% 1462
2019
Q4 		– Sell
-2
Closed -$146 – 2121
2019
Q3 		$1K Buy
+2
New +$145 ﹤0.01% 2119

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Federated Hermes's MRSN Position: Q1 2025 in Review

Federated Hermes sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 7,349 shares — an estimated $263K sold.

Federated Hermes first reported a position in MRSN in Q3 2019 and held it in 13 quarters. The position peaked at $5.19M in Q3 2020. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Federated Hermes reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Federated Hermes sold 7,349 Mersana Therapeutics shares in Q1 2025, an estimated $263K.
  • Federated Hermes first reported a position in Mersana Therapeutics in Q3 2019 and held it in 13 quarters.
  • Federated Hermes's Mersana Therapeutics position peaked at $5.19M in Q3 2020.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Federated Hermes's 13F filing for Q1 2025, filed 8 May 2025.